Portal de Periódicos da CAPES

A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis

2020; Informa; Volume: 33; Issue: 2 Linguagem: Inglês

10.1080/09546634.2020.1773379

1471-1753

Maria Concetta Fargnoli, Maria Esposito, Silvia Mariel Ferrucci, Giampiero Girolomoni, Anna Maria Offidani, Annalisa Patrizi, Ketty Peris, Antonio Costanzo, Giovanna Malara, Giovanni Pellacani, Marco Romanelli, Paolo Amerio, Antonio Cristaudo, Maria Laura Flori, Alberico Motolese, P. Betto, Cataldo Patruno, Paolo D. Pigatto, Camilla Peccianti, Giuseppe Stinco, Iris Zalaudek, Luca Bianchi, Valeria Boccaletti, Serafinella Patrizia Cannavò, Francesco Cusano, Serena Lembo, R. Mozzillo, Rosella Gallo, Concetta Potenza, Franco Rongioletti, R. Tiberio, Teresa Grieco, Giuseppe Micali, Severino Persechino, M. Pettinato, Sabina Pucci, Luca Stingeni, Cristiano Caruso, Giuseppe Argenziano,

Asthma and respiratory diseases

Dear Editor,The long-term efficacy and safety of dupilumab has been demonstrated in clinical trials (1,2) and only in few real-world studies (3–5). We recently published a retrospective real-life I...